Clinical features and treatment effect of HIV-associated immune thrombocytopenia—single center Ten-Years data summary

Figures & data

Table I. Clinical characteristics of 45 patients with HIV combined with ITP.

Clinical characteristics	N = 45
Age (year, M, range)	43 (8–71)
Genders (n,%)
Male	26 (57.8%)
Female	19 (42.2%)
ITP phases (n,%)
Newly diagnosed	25 (55.6%)
Persistent	7 (15.6%)
Chronic	13 (28.8%)
HIV stage (n,%)
I-II	41 (91.1%)
III-IV	4 (8.9%)
Platelet count (×10^9/L) (n,%)
≤20	37 (82.22%)
>20	8 (17.78%)
Hemoglobin (g/L) (n,%)
≥90	31 (68.9%)
<90	14 (31.1%)
Bleeding symptoms (n,%)	35 (77.8%)
Hemorrhage site (n,%)
Skin petechiae	19 (42.2%)
Nose bleeding	9 (20.0%)
Gum bleeding	7 (15.6%)
Heavy menstrual flow	5 (11.1%)
Gastrointestinal bleeding	1 (2.2%)
HIV infection route (n,%)
Sexual transmission	27(60.0%)
Intravenous injection	8 (17.8%)
Unknown routes of infection	10 (22.2%)
CD4+ T-cell count(cells/µL) (n,%)
<200	18 (40.0%)
≥200	27 (60.0%)
Co-infection (n,%)
Hepatitis B	5 (11.1%)
Hepatitis C	11 (24.4%)
Syphilis	3 (6.7%)
Tuberculosis	3 (6.7%)
EBV	1 (2.2%)
HAART treatment (n,%)
Yes	45 (100.0%)
No	(0.0%)

ITP: primary immune thrombocytopenia; HIV: Human Immunodeficiency Virus; EBV: Epstein-Barr Virus; HAART: highly active antiretroviral therapy.

Figure 1. (a) There was no significant difference in platelet counts before and after treatment between patients who had used HAART before admission and those who had reduced platelets as the initial symptom; (b) There was no significant difference in platelet counts before and after treatment between patients who used different HAART. the platelet counts after treatment were significantly higher than before treatment in all groups. (c, d) There were no significant differences in treatment efficiency and recurrence rates between HAART use before admission, different HAART regimens, and different ITP treatment regimens.

Figure 2. Changes in platelet counts with different ITP regimens. Except for the HAART+other group, the platelet counts of patients in all groups were higher after treatment than before.

Figure 3. (a) There was no statistically significant difference in platelet counts before and after treatment at different ITP phases. (b) There was no significant correlation between CD4+ T-cell count and platelet count. (c) Platelet count in HIV patients co-infected with hepatitis C was significantly lower before treatment than that in HIV patients without co-infected with hepatitis C. The platelet counts of patients co-infected with hepatitis B or hepatitis C were all higher after treatment than before. (d, e) the newly diagnosed ITP showed a higher response rate and a lower relapse rate than persistent and chronic ITP. CD4+ T-cell counts, co-infected with hepatitis B virus, and co-infected with hepatitis C virus had no significant effect on the treatment effect and relapse rate of patients with HIV-associated thrombocytopenia.